american heart association glp-1 Abstract TH929: Receptor Agonist Medication Use Persistence in the All of Us Research Program 2025 AHA Scientific Sessions -

This has raised concerns about their impact on cancer risk, spurring extensive research

Learn how Sermorelin therapy helps regulate hormones, enhance recovery, support restful sleep, and promote steady energy for daily resilience.

Today, Secretary Greenstein, Seth Gold, and Senator Boudreaux testified before the House Appropriations Committee on SB 433, which covers GLP-1 medications in the Medicaid program for residents affected only by obesity

Neurodegenerative diseases, including Alzheimers Disease (AD) and Parkinsons Disease (PD) are common complications of diabetes, arising from insulin resistance, inflammation, and other pathological processes in the central nervous system

Nonalcoholic fatty liver disease (NAFLD) is a prevalent metabolic liver disease closely associated with the epidemics of obesity and type 2 diabetes mellitus (T2DM), but without licensed pharmacological treatment to date

What are glucagon-like peptide-1 (GLP-1) receptor agonists?Glucagon-like peptide-1 receptor agonists, commonly known as GLP-1 drugs, are a class of peptide medications (not dietary supplements) primarily used to treat type 2 diabetes (T2D) and obesity